Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

NetScientific plc chief hails progress at Vortex Biosciences

Monday, November 7, 2016 7:29
% of readers think this story is Fact. Add your two cents.

(Before It's News)

NetScientific plc (LON:NSCI) chief executive and chairman Francois Martelet hailed recent news from portfolio company Vortex Biosciences as a “very important” milestone.
Vortex has been awarded a CE Mark for its circulating tumour cell (CTC) capture system and has registered a Class I medical device with the US FDA (Food and Drug Administration).
It means moving the selling of the VTX-1 Liquid Biopsy System closer in Europe and the USA – firstly for research use only.
Martelet said it was an exciting validation of the technology, which offers a high level of purity and collection efficiency against other methods of cell capture.
“Most patients don’t die because of their tumours. Most patients die because of circulating tumour cells, which down the road, lead to metastasis,” he highlighted.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.